Genotype-guided Supportive Care in Symptom Treatment of Cancer Patients
Stopped early · Not applicable
Conditions studied: Chemotherapy, Supportive Care, Genotyping
In brief
Cancer patients often require administration of multiple supportive care pharmacotherapies while receiving chemotherapy regardless the type of cancer. Supportive care therapies are commonly prescribed to nearly all cancer patients and could include antiemetics (ondansetron), pain management (opiates), GI protection (PPIs), antidepressants (select SSRIs), anticoagulation (warfarin) and antifungal prophylaxis (voriconazole). These are all are associated with known pharmacogenetic interactions, which in some cases render the drugs ineffective or toxic. This could result in negative impacts on quality of life in patients who are already undergoing complicated and costly anticancer regimens. Pharmacogenetic-guided therapy based on an individual patient's genetic profile could potentially target symptoms for which an individual is uniquely susceptible, guiding use of medications that are most likely to be effective, thereby reducing unnecessary physical complications and financial strain. It is hypothesized that patients in the genotype intervention arm will report lower scores for overall symptom distress as compared to patients in the delayed genotype intervention arm following initiation of chemotherapy.
Key facts
- Study ID
- NCT03924557
- Run by
- University of Florida
- People needed
- 148
- Starts
- 2019-07-09
- Expected to finish
- 2021-04-13
- Last updated by the study team
- 2023-01-27
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Must have a clinical diagnosis of solid tumor cancer and be seeking treatment and supportive care at the UF Health Cancer Center (Medical Plaza)
- Patients must plan to receive chemotherapy known to be associated with the need for supportive care within 30 days of enrollment
- Life expectancy must be greater than 6 months
- Must have Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
- Written informed consent obtained from the patient
- The ability for the patient to comply with all the study-related procedures.
You may not qualify if…
- Patients unwilling or unable to provide voluntary informed consent
- Patients who are unwilling or unable to comply with protocol requirement and/or follow-up procedures
- Patients planned to undergo cancer therapy other than chemotherapy (i.e., radiation, surgery or hormonal treatment alone)
- Prisoners or patients who are involuntarily incarcerated. Patients who are compulsorily detained for treatment of either a psychiatric or physical illness.
Where it is running
- UF Health at the University of Florida — Gainesville, Florida, United States
- UF Health Cancer Center — Gainesville, Florida, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.